Dyslipidemia in Visceral Obesity: Mechanisms, Implications, and Therapy

Author： Dick C. Chan   Hugh P.R. Barrett   Gerald F. Watts  

Publisher： Adis International

ISSN： 1175-3277

Source： American Journal of Cardiovascular Drugs, Vol.4, Iss.4, 2004-01, pp. : 227-246

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The role of NPY in metabolic homeostasis: implications for obesity therapy

By Wieland H.A.   Hamilton B.S.   Krist B.   Doods H.N.  

Expert Opinion on Investigational Drugs, Vol. 9, Iss. 6, 2000-06 ,pp. : 1327-1346

Informa Healthcare

Access to resources Recommend Favorite

Ezetimibe Therapy for Dyslipidemia: An Update

By  

Current Pharmaceutical Design, Vol. 19, Iss. 17, 2013-05 ,pp. : 3107-3114

Bentham Science Publishers

Access to resources Recommend Favorite

Drug Combinations for Dyslipidemia and Obesity Treatment in Metabolic Syndrome

By  

Current Pharmaceutical Design, Vol. 15, Iss. 29, 2009-10 ,pp. : 3446-3462

Bentham Science Publishers

Access to resources Recommend Favorite

There is a smorgasbord of options in the management of dyslipidaemia in visceral obesity

By Adis International Limited  

Drugs & Therapy Perspectives, Vol. 21, Iss. 8, 2005-08 ,pp. : 10-14

Adis International

Access to resources Recommend Favorite

Fenofibric Acid: In Combination Therapy in the Treatment of Mixed Dyslipidemia

By Yang Lily P.H.   Keating Gillian M.  

American Journal of Cardiovascular Drugs, Vol. 9, Iss. 6, 2009-12 ,pp. : 401-409

Adis International

Access to resources Recommend Favorite